Joel Mokyr, Philippe Aghion and Peter Howitt have been awarded the 2025 Nobel Prize in Economics. (Photo by Jonathan Nackstrand / AFP) / ALTERNATIVE CROP (Photo by JONATHAN NACKSTRAND/AFP via Getty ...
A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences announced on Wednesday that it acquired the rights to a blood-based ...
Gilead Sciences broke into the field of cancer cell therapies through an acquisition. Now it’s aiming to be part of the next generation of such therapies by buying clinical-stage Interius ...
North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...
The subject area represents the next stage of the database’s evolution, and heralds other proposed changes to journal selection and article categorization. The first Nature Index tables in the applied ...
Recent Exact Sciences Corporation financials show accelerating revenue growth and stable margins, despite ongoing investments in screening and MRD. While EXAS maintains leadership in stool-based CRC ...
The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences, makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results